Overview

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with mild to moderately severe Crohn's disease who have fistulas. The study will test whether or not patients receiving AST-120 experience a greater reduction in number of draining fistulas and improvement of their other Crohn's disease symptoms versus patients who receive placebo (material that does not contain any active medication).
Phase:
Phase 3
Details
Lead Sponsor:
Ocera Therapeutics